SCHEMBL17015774

SCHEMBL17015774

O=C(c1ccc(-n2c3ccccc3c3ccc4c(ccn4-c4cc(-c5ccccc5)cc(-c5ccccc5)c4)c32)cc1)c1ccc2ccccc2c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 3/20 0.35
MAPK1 P28482 2/20 0.35
GMNN O75496 1/20 0.35
LMNA P02545 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
HPGD P15428 1/20 0.35
ALOX15 P16050 1/20 0.35
TSHR P16473 1/20 0.35
NFKB1 P19838 1/20 0.35
CNR1 P21554 1/20 0.35
CYP2C19 P33261 1/20 0.35
THPO P40225 1/20 0.35
MTOR P42345 1/20 0.35
BLM P54132 1/20 0.35
PMP22 Q01453 1/20 0.35
HIF1A Q16665 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17015698 0.94 MAPK1 (0.36) CNR2MAPK1GMNNLMNACYP1A2
SCHEMBL17015779 0.94 CLK1 (0.36) CNR2MAPK1GMNNLMNACYP1A2
SCHEMBL17015771 0.92 CNR2 (0.36) CNR2LMNAHPGDALOX15TSHR
SCHEMBL17016183 0.91 CNR2 (0.38) CNR2MAPK1GMNNLMNACYP1A2
SCHEMBL17015226 0.91 CNR2 (0.38) CNR2MAPK1GMNNLMNACYP1A2
SCHEMBL17015697 0.89 CLK1 (0.36) CNR2MAPK1GMNNLMNACYP1A2
SCHEMBL17016175 0.87 ROCK2 (0.40) CNR2MAPK1GMNNLMNACYP1A2
SCHEMBL17015776 0.87 CNR2 (0.36) CNR2HPGDCNR1SMN1; SMN2ALDH1A1
SCHEMBL17015775 0.85 SRC (0.45) CNR2MAPK1GMNNLMNACYP1A2
SCHEMBL17015230 0.85 CLK1 (0.40) CNR2MAPK1GMNNLMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 US disclosed
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME INMT, IDO1, IDO2 CNR2 1583/4885MAPK1 1743/4885GMNN 1879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.